Are Weight-Loss Drugs a Lifelong Commitment?
A recent study in the BMJ (https://www.bmj.com/content/392/bmj-2025-085304) has reignited a fascinating debate: what happens when patients stop taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs)? These drugs, used for weight loss and diabetes management, have shown impressive results, but the real question is, are they a temporary fix or a lifelong commitment?
But here's the twist: the study found that weight often returns swiftly after stopping treatment, sometimes faster than with other weight-loss methods. And it's not just weight; blood pressure, blood glucose, and blood lipids also revert to pre-treatment levels.
This raises a crucial question: should patients even start these medications? Experts weigh in.
Predictable Weight Regain, but Not the Real Issue
Professor Clare Collins from the University of Newcastle explains that rapid weight regain after stopping treatment is expected. It's a fundamental principle of chronic disease management: when you stop an effective treatment, the condition returns. But the real concern is the deterioration of metabolic markers, which could have more significant clinical implications.
Understanding the Rebound Effect
Associate Professor Trevor Steward clarifies that the rebound effect is not a failure of the drugs or patients. GLP-1 RAs amplify existing hormonal signals, especially those regulating appetite, digestion, and satiety. The benefits rely on sustained hormone exposure. When treatment stops, the body's systems are no longer influenced, leading to rapid weight regain.
And here's where it gets controversial: these drugs may cause a stronger 'slingshot effect,' leading to faster weight loss but potentially more rapid regain. Emerging evidence suggests they cross the blood-brain barrier, impacting reward pathways linked to appetite and environmental food cues.
The Role of Nutrition: A Missing Piece of the Puzzle
Prof. Collins highlights that dietary changes are often overlooked in trials. Most provide standardized advice but don't track dietary intake, making it challenging to understand the long-term impact on eating patterns. Reduced intake doesn't guarantee a healthier diet, and micronutrient deficiencies can emerge. Pharmacists, with their frequent patient contact, can play a vital role in identifying issues and referring patients to dietitians for medical nutrition therapy.
Long-Term Strategy: A Balancing Act
A/Prof. Steward argues that, given the risks of long-term obesity, continued therapy might be a safer option for some. For those with repeated weight loss and regain cycles, GLP-1 RAs could be a lifelong treatment, similar to medications for chronic conditions. However, he stresses the importance of setting clear expectations before treatment, as many patients may take these drugs for non-health reasons, like an upcoming wedding.
A thought-provoking question: Are these drugs a temporary solution or a long-term commitment? As evidence evolves, so must clinical messaging. With over half a million Australians taking these medications, clearer guidance on tapering and maintenance is needed. Is it time to rethink our approach to weight loss and management?
